Radiogardase (prussian blue (insoluble))
Antidote - GI Insoluble Metal Chelators Oral Capsule
Last reviewed · Source: First Databank (FDB) drug data
Overview
Prussian blue (insoluble), a crystal lattice of ferric hexacyanoferrate (II), is an ion-exchange medium with high affinity for cesium and thallium, including radioactive isotopes of these metals.
Prussian blue (insoluble), a crystal lattice of ferric hexacyanoferrate (II), is an ion-exchange medium with high affinity for cesium and thallium, including radioactive isotopes of these metals. Following oral administration, prussian blue is not appreciably absorbed through the intact GI wall; clearance of prussian blue depends on GI transit time. Following systemic absorption, cesium and thallium are widely distributed throughout the body; cesium and thallium are excreted into the intestine and undergo enterohepatic circulation.
Following oral administration of prussian blue, the drug binds cesium and/or thallium in the GI tract following ingestion or biliary excretion, thus preventing the absorption or reabsorption, respectively, of these metals and increasing the rate of their elimination as insoluble complexes in feces.
Prussian blue also may bind other elements (e.g., potassium).
Generic name: prussian blue (insoluble)
Drug class: Antidote - GI Insoluble Metal Chelators
Therapeutic class: Antidotes and other Reversal Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Radiogardase
Indications
The following indications are listed for Radiogardase:
- Exposure To Cesium Radiation
- Thallium Poisoning
Also known as: Accidental Poisoning By Thallium, Accidental Poisoning By Thallium Compounds, Cesium Intoxication, Radiocesium Poisoning, Thallium Intoxication.
Dosing
No dosing information is available for this tab.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Radiogardase 0.5 Gm Capsule | Maintenance | Take 6 capsules (3 gram) by oral route 3 times per day. |
No dosing information is available for this tab.
Drug interactions
The possibility exists that prussian blue may bind some orally administered drugs (e.g., tetracycline) and/or essential nutrients. Serum concentrations and/or clinical response should be monitored in patients receiving orally administered, clinically important drugs.
Data from animal studies indicate that concomitant use of prussian blue with other radioprotectants does not affect efficacy of prussian blue in the management of internal contamination with radioactive cesium (137Cs).
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
None.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
- Cardiac arrhythmia
- Constipation
- Gastrointestinal hypomotility
- Hypokalemia
Adverse reactions
Adverse effects occurring in patients receiving prussian blue include constipation and GI distress. Blue discoloration of sweat and tears has been reported in patients receiving long-term therapy with prussian blue.
Less Frequent
- Hypokalemia
More Frequent
- Constipation
- Discolored feces
Precautions
No enhanced messaging available.
Prussian blue (insoluble) is used for the treatment of known or suspected internal contamination with radioactive cesium and/or radioactive or nonradioactive thallium in pediatric patients 2 years of age or older. Safety and efficacy and dosage recommendations for prussian blue in pediatric patients have been extrapolated from experience in adults and supported by experience in pediatric patients (4-12 years of age) who received prussian blue for the treatment of heavy internal contamination with 137Cs in a 1987 incident in Brazil. In that incident, the rate of elimination of radioactivity in pediatric patients receiving prussian blue in a dosage of 1 g 3 times daily was similar to the rate in adults receiving prussian blue 3 g 3 times daily. Children 2-4 years of age are expected to have biliary and GI function comparable to that of a 4-year-old child. There are variations in the developmental maturity of the biliary system and GI tract of infants younger than 2 years of age; dosing recommendations have not been established for neonates or infants (i.e., pediatric patients younger than 2 years of age).
Category C. (See Users Guide.)
Prussian blue is unlikely to distribute into breast milk. Because cesium and thallium are distributed into human breast milk, women contaminated with these metals should not breast-feed infants.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Thallium poisoning | ||
| T56.811A | ICD10CM | Toxic effect of thallium, accidental (unintentional), initial encounter |
| T56.812A | ICD10CM | Toxic effect of thallium, intentional self-harm, initial encounter |
| T56.813A | ICD10CM | Toxic effect of thallium, assault, initial encounter |
| T56.814A | ICD10CM | Toxic effect of thallium, undetermined, initial encounter |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.